| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.2 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | epigallocatechin-3-monogallate | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |